Suzuki S et al. – MAGE-A10 is a possible target in active immunotherapy for advanced stomach cancer Methods
Analysis of tumor samples from 71 pts with stomach cancer: 41 with liver metastasis (grp A) and 15 pts each in stages II–IV (grp B) and stage I (grp C) without liver metastasis
Immunohistochemical analysis of MAGE-A protein expression by 6C1 monoclonal antibody
In situ hybridization with a cRNA probe to detect MAGE-A10 mRNA expression
Results
Grp A: MAGE-A protein and MAGE-A10 mRNA expressions: 65.9% and 80.5% of pts, respectively
Significantly higher expression of both protein and gene in grp A vs B and C
MAGE-A10 mRNA expression in liver metastasis in 8 (88.9%) of 9 pts
Concordant rate between MAGE-A family protein expression and MAGE-A10 mRNA expression in primary sites: 81.7%
MAGE-A10 gene expression associated with reduced survival
See all
